Naslov
Overall survival (OS) results of patients with left-sided metastatic colorectal cancer (mCRC) in real life – experience from University Hospital for Tumors Zagreb, Croatia

Autori
Pavlović, Mirjana ; Šeparović, Robert ; Lepetić, Petra ; Tečić Vuger, Ana ; Vazdar, Ljubica

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Izvornik
Abstracts. U:Annals of Oncology 31(S3) / - , 2020, 147-148

Skup
ESMO World Congress on Gastrointestinal Cancer 2020

Mjesto i datum
Online, 01.07.2020. - 04.07.2020

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
metastatic colorectal cancer ; real world data ; Croatia

Sažetak
According to 2016. Eurostat cancer statistics Croatia has the second highest standardised death rate for CRC among the EU Member States. Tempted with that fact we tryed to analyse the reasons behind this bad result in our cohort of patients. Available real wold data suggest that median OS of patients with left-sided mCRC is 22 to 25 months. Overall, around 750 patients are treated each year due to mCRC in Croatia. Of that, 70-75% are left- sided tumors. We present survival results of patients treated for left-sided mCRC in our institution. We conducted retrospective analysis on consecutive sample of all patients who started their treatment with chemotherapy dublet +/- biological agent between January 1st, 2016 and December 31st, 2017. OS was calculated from the start of induction therapy to deaTotal of 112 patients were analysed. Median age was 62 (39- 85), 60% of patients were men and 40% women. At the time of diagnosis as much as 60% of patients were metastatic and 60% of all patients had more than one metastatic site. Chemotherapy without biological agent was used in 25% of patients. Irinotecan based induction chemotherapy regimen was used in 81% of patients. Among patients with biological therapy 66% received bevacizumab and 34% anti- EGFR drug. When analyzing two-year follow-up outcomes, the median PFS for 1st line treatment was 11 months, 38% of patient received 2nd line treatment with median PFS of 5 months and only 5% received 3rd line treatment with median PFS of 5 months. Two- year OS rate was 50%. More than quarter of patients are still on therapy (27%) and median duration of treatment is 32.5 months. th of patient. Kaplan-Meier curves were used to estimate median survival and survival rates. To best of our knowledge this is the first report of overall survival data of patients with mCRC in Croatia to date. Bad trend in OS results could be partly determined by late diagnosis and the fact that as much as 60% of patients were high risk patients with initially metastatic disease and high tumor burden. This suggests that perhaps more effort should be made to diagnose the disease in earlier stage. The lack of multidisciplinarity in our institution probably has the major impact on our results.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA